Gilteritinib for Patients with Newly Diagnosed AML

Data from the worldwide MORPHO study, presented by Professor Mark Levis, aims to answer the question if patients with newly diagnosed FLT3-ITD-positive acute myeloid leukemia (AML) should be treated with gilteritinib as maintenance therapy following allogeneic stem cell transplant. Even though not all patients seem to benefit from this treatment, Mark Levis highlights that around the 50 % of patients being MRD-positive, gilteritinib appears to have a significant effect.